Long-Term Monitoring and Knowing Your Red Flags
At a Glance
People with Chanarin-Dorfman syndrome need individualized, long-term checks of liver, muscle, hearing, vision, and thyroid health. Stable liver enzymes do not rule out liver scarring, and new jaundice, swelling, confusion, bleeding, dark urine, or breathing problems require urgent care.
Living with Chanarin-Dorfman Syndrome (CDS) is a marathon, not a sprint. Because this condition can cause progressive complications across multiple organ systems, the goal of long-term care is identifying changes early so they can be managed before they become crises [1][2].
Your Long-Term Surveillance Plan
There is no “one-size-fits-all” schedule for CDS monitoring. Your specialists will create a plan tailored to your age, genotype, and current symptoms. While a comprehensive visit every 6 to 12 months is a common example, children, individuals with active liver disease or fibrosis, or those taking potentially hepatotoxic drugs will need much more frequent review [2][3].
| What is Monitored | Common Tests | Why it Matters |
|---|---|---|
| Liver Health | Enzymes (AST, ALT, GGT), Synthetic function (Bilirubin, Albumin, INR), Platelets, Ultrasound, and Elastography [4] | To monitor for fat buildup (steatosis) and screen for scarring (cirrhosis) or liver failure [5][6]. |
| Muscle Function | Creatine Kinase (CK) and physical strength exams [4] | To track variable myopathy (muscle weakness), which can progress over time [3]. |
| Hearing | Formal audiometry (hearing test) [2] | Sensorineural hearing loss has been reported in many patients and can be present before you notice it [2]. |
| Vision | Dilated eye exams [7] | To check for cataracts or eye-surface irritation (keratopathy) [4][8]. |
| Thyroid | TSH and T4 blood tests [2] | Thyroid issues have been reported in some patients [2]. |
A Note on Liver Tests: It is vital to understand that AST and ALT enzyme levels do not reliably show how much fibrosis or loss of liver function is present. Stable or mildly abnormal enzymes do not rule out significant disease, which is why synthetic function tests (like INR) and fibrosis assessments (like elastography) are critical parts of hepatology care.
Triage: Understanding Symptoms and Urgency
It is important to know which symptoms are expected parts of life with CDS, which require same-day contact with your specialist, and which are medical emergencies.
Usually Not an Emergency
The following are common, ongoing features of CDS. If they are unchanged and unaccompanied by warning symptoms, they can usually be discussed at your next scheduled visit:
- Typical Skin Flares: Mild increases in scaling or redness that respond to your usual emollient routine [9].
- Baseline Weakness: A steady, unchanging level of difficulty with physical activity [3].
- Stable Liver Labs: Lab results that remain at their previously established baseline, provided you are under active hepatology surveillance [4].
Caution: A new skin flare or “baseline” weakness is not automatically benign if it is sudden or accompanied by infection, fever, or dark urine.
Same-Day Specialist Contact
Contact your care team immediately (do not wait for a routine appointment) if you experience:
- Fever or signs of suspected skin infection (painful redness, pus, foul-smelling drainage).
- Inability to drink fluids or persistent vomiting.
- Sudden changes in muscle strength or severe heat illness/exhaustion.
Urgent Red Flags (Seek Emergency Care)
The most critical long-term risk in CDS is hepatic failure (liver failure). Seek immediate emergency medical attention if you or your child experience [6][1][4]:
- Worsening Jaundice: A new or rapid yellowing of the whites of the eyes or the skin.
- Abdominal Swelling (Ascites): A rapid increase in the size of the abdomen or a “tight” feeling in the belly, indicating fluid buildup.
- Confusion or Extreme Sleepiness: Signs of encephalopathy, where the liver can no longer filter toxins from the blood.
- Internal Bleeding: Vomiting blood (which may look like coffee grounds) or passing black, tarry stools.
- Severe Muscle Breakdown: Sudden, severe muscle pain accompanied by dark “cola-colored” urine and extreme weakness.
- Dehydration or Breathing/Swallowing Difficulty.
Quality of Life and Survivorship
Beyond medical tests, it is vital to address the daily reality of CDS—the fatigue, the social impact of visible skin scaling, and the emotional stress of chronic illness [10][11].
- Pacing and Accommodations: Fatigue is a common symptom. Learning to balance activity with rest is important [12]. Discuss school or workplace accommodations (such as temperature control or specialized seating) with your team.
- Mental Health Support: Connecting with other families through rare disease networks can reduce isolation. Many patients benefit from working with a therapist who specializes in chronic illness.
- Health Binders: Keeping your own “health binder” with copies of all your surveillance results empowers you as an active partner in your care, ensuring no specialist misses a critical change [12].
Common questions in this guide
How often are checkups and tests needed for Chanarin-Dorfman syndrome?
Can normal AST and ALT levels rule out liver damage in CDS?
Which symptoms of Chanarin-Dorfman syndrome require emergency care?
When should I contact my CDS specialist instead of waiting for a routine visit?
What tests are used to monitor Chanarin-Dorfman syndrome?
How can I notice a meaningful change in my usual muscle weakness?
Get notified when new evidence is published on Neutral lipid storage disease with ichthyosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients.
Pennisi EM, Arca M, Bertini E, et al.
Orphanet journal of rare diseases 2017; (12(1)):90 doi:10.1186/s13023-017-0646-9.
PMID: 28499397 - 2
Thyroid involvement in Chanarin-Dorfman syndrome in adults in the largest series of patients carrying the same founder mutation in ABHD5 gene.
Louhichi N, Bahloul E, Marrakchi S, et al.
Orphanet journal of rare diseases 2019; (14(1)):112 doi:10.1186/s13023-019-1095-4.
PMID: 31118107 - 3
Long-term neuromuscular, cardiac and liver outcomes in an adult man affected with Chanarin-Dorfman syndrome.
Noman K, Tridimas A, Lilleker JB, et al.
Molecular genetics and metabolism reports 2025; (45()):101265 doi:10.1016/j.ymgmr.2025.101265.
PMID: 41127218 - 4
Chanarin-Dorfman syndrome.
Kalyon S, Gökden Y, Demirel N, et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2019; (30(1)):105-108 doi:10.5152/tjg.2018.18014.
PMID: 30457558 - 5
Chanarin-Dorfman Syndrome: A comprehensive review.
Cakmak E, Bagci G
Liver international : official journal of the International Association for the Study of the Liver 2021; (41(5)):905-914 doi:10.1111/liv.14794.
PMID: 33455044 - 6
Liver Transplant Outcome in Chanarin-Dorfman Syndrome: A Rare Lipid Storage Disease.
Milani S, Ashrafzadeh K
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2024; (22(12)):961-963 doi:10.6002/ect.2024.0280.
PMID: 39810583 - 7
Navigating Surgical Challenges: Managing Juvenile Glaucoma in a Patient with Dorfman-Chanarin Syndrome.
Anton N, Dohotariu FC, Pîrvulescu RA, et al.
Biomedicines 2024; (12(10)) doi:10.3390/biomedicines12102164.
PMID: 39457477 - 8
Ichthyosis, cataracts, and motor delay in an infant: A case of Chanarin-Dorfman syndrome.
Luu Y, Pithadia DJ, Teng J, Khuu P
Pediatric dermatology 2023; (40(5)):879-881 doi:10.1111/pde.15258.
PMID: 36709747 - 9
A novel mutation of ABHD5 gene in a Chanarin Dorfman patient with unusual dermatological findings.
Eskiocak AH, Missaglia S, Moro L, et al.
Lipids in health and disease 2019; (18(1)):232 doi:10.1186/s12944-019-1181-6.
PMID: 31883530 - 10
Toward an Understanding of GSD5 (McArdle disease): How Do Individuals Learn to Live with the Metabolic Defect in Daily Life.
Karazi W, Coppers J, Maas D, et al.
Journal of neuromuscular diseases 2024; (11(1)):103-116 doi:10.3233/JND-230027.
PMID: 38108358 - 11
A retrospective study of eating and psychosocial problems in patients with hepatic glycogen storage diseases and idiopathic ketotic hypoglycemia: Towards a standard set of patient-reported outcome measures.
Venema A, Peeks F, de Bruijn-van der Veen M, et al.
JIMD reports 2022; (63(1)):29-40 doi:10.1002/jmd2.12253.
PMID: 35028269 - 12
Experiences of living with GSD5 (McArdle) disease: challenges and strategies. A qualitative study in the Netherlands.
van Haaren-Pater R, Karazi W, Maas D, et al.
Disability and rehabilitation 2025; (47(14)):3649-3656 doi:10.1080/09638288.2024.2424439.
PMID: 39523819
This page is for informational purposes only and does not constitute medical advice. Use it to discuss monitoring and warning signs with your Chanarin-Dorfman care team, and seek emergency help for urgent symptoms.